Skip to main content
SpringerLink
Log in

EGFR-Hemmung bei Ovarialkarzinom wirksam?

  • Literatur kompakt_Mammakarzinom und gynäkologische Tumoren
  • Published:
Im Focus Onkologie Aims and scope

In Phase-II-Studien hatten die Tyrosinkinaseinhibitoren (TKI) Erlotinib und ­Gefitinib eine Wirksamkeit beim Orvarialkarzinom gezeigt. Nun liegt die erste größere randomisierte Studie vor – mit enttäuschendem Ergebnis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Vergote IB et al. Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. J Clin Oncol. 2014;32(4):320-6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Friederike Klein

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, F. EGFR-Hemmung bei Ovarialkarzinom wirksam?. Im Focus Onkologie 17, 27 (2014). https://doi.org/10.1007/s15015-014-1212-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1212-0

Search

Navigation